KR101114690B1 - A composition comprising the extract of Gentiana scabra var. buergeri max for preventing and treating drug intoxication or withdrawal symptoms - Google Patents

Abstract

The present invention relates to a composition containing a chodote extract as an active ingredient, specifically, the chodote extract of the present invention, as well as the effect of reducing the amount of walking activity which is a behavioral sensitization reaction used as an indicator of drug addiction By confirming the rapid decrease in c-Fos expression, which is an indicator of neuronal activity in the nucleus and striatum of the brain, the composition may be useful as a pharmaceutical composition or health functional food for the prevention and treatment of drug addiction and withdrawal symptoms. have.

Super gentian, ambulatory activity, c-Fos, cocaine, withdrawal symptoms

Description

A composition comprising the extract of Gentiana scabra var. buergeri max for preventing and treating drug intoxication or withdrawal symptoms}

The present invention relates to a pharmaceutical composition or health functional food for the prevention and treatment of drug addiction and withdrawal symptoms containing choyong chok extract as an active ingredient.

Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine, Ⅰ. Dopamine axon terminals. J Neurosci. 13 (1) , pp. 266-275, 1993

Pettit HO et al., Extracelluar concentration of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem. 55 (3) , pp. 798-804, 1990

Hurd YL et al., Cocaine reinforcement and extracellular dopamine overflow in rat nucleus accumbens: an in vivo microdialysis study. Brain Res. 498 (1) , pp. 199-203, 1989

Wiechman BE et al., Locomotor activity in morphine-treated rats: effects of and comparisons between cocaine, procaine, and lidocaine. Pharmacol. Biochem. Behav. 15 (3) , pp. 425-433, 1981

Einhorn, LC, et al., Electrophysiological effect of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area, J Neurosci., 8 (1) , pp. 100-112, 1988

Parada A., et al., Neuropharmacology , 39 (9) , pp. 1645-1652, 2000

Anderson SM et al., Administration of the D1-like dopmine receptor antagonist SCH-23390 into the medial nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug-seeking behavior in rats. Psychopharmacology (Berl). 168 (1-2) , pp. 132-138, 2003

[Document 8] Park, Jong-hee, Lee, Jung-gyu. (Commercial) Illustration of medicinal plants. pp.306-308, 2000

[Document 9] 文 미치는 豪 外, The Effect of Ginseng Cultivated Water on the Induced Mice of Stones, Dae-Sung, J., 8 , pp.141-156, 1991

[10] Effects of Han Sang-won, Yongdamcho and Shiho-su-acupuncture on CCl4-induced Injury in Rats, Journal of Korean Acupuncture and Moxibustion Society, 10 (1) , pp.297-313, 1993

[11] Karasinska JM., Et al., Eur Neurosci ., 22 (7) , pp.1741-1750, 2005

Document 12 NATHALIE THIRIET et al., Ann NY Acad. Sci ., 914 , pp. 46-57, 2000

[Reference Document 13] Hyung-Chul Lee et al., Journal of Oriental Medical Pathology , 15 (4) , pp.543-47, 2001

The spread of drug addiction is one of the most important modern social problems due to the development of scientific civilization and the stress of modern people due to the rapid economic society. Drug refers to a substance used to prevent or treat a disease, and refers to a substance that causes a change in physical function. Abuse of these drugs raises the problem of self-destruction both physically, mentally and socially on the negative side. Drug addiction refers to a physical reaction to drugs such as opiates, neurostabilizers or alcohol. Drug addiction has symptoms of tolerance, withdrawal symptoms and habituation, which can mean loss of control due to drug use. Recent drug abuse is one of the world's most serious mental illnesses caused by the increasing number of adolescents and female drug abusers. The development of drugs for addictive drugs is urgently needed.

As a solution of drug addiction, various social policies, treatments, and rehabilitation programs are being implemented, but they have limitations as a fundamental treatment measure.

Addictive drugs, such as cocaine, amphetamine, morphine, and nicotine, cause behavioral sensitization in behaviors, which are called repeated or small amounts of addictive drugs. Intermittent administration results in a gradual increase in locomotor activity and homotypy. The developmental stage (Development = induction of sensitization) and the development once developed. The expression of sensitization, which is a relatively long-lasting state of activity, is represented by the neural substrate responsible for this phenomenon, which is the mesolimbic dopamine pathway in the central nervous system. It is known to be the target region of the nucleus accumbens (NAc) and striatum (Kalivas PW, D). uffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine, I. Dopamine axon terminals.J Neurosci. 13 (1) , pp.266-275, 1993), suggests that addictive drugs increase the amount of gait activity following drug administration. (Pettit HO et al., Extracelluar concentration of cocaine and dopamine are enhanced during chronic cocaine administration.J Neurochem. 55 (3) , pp.798-804, 1990; Hurd YL et al., Cocaine reinforcement and extracellular dopamine overflow in rat nucleus accumbens: an in vivo microdialysis study. Brain Res. 498 (1) , pp. 199-203, 1989; Wiechman BE et al., Locomotor activity in morphine-treated rats: effects of and comparisons between cocaine, procaine, and lidocaine. Pharmacol. Biochem. Behav. 15 (3) , pp.425-433, 1981), the amount of gait activity is used as an indicator of major drug addiction.

Cocaine is induced through drug-intensifying effects. The factor affecting this behavioral change is the activation of the dopamine (DA) neurotransmitter. In particular, cocaine administration compensates and strengthens the ventral tegmental area. The central brain limbic system, which originates in the A10 neuron in the area (VTA) and is projected to the nucleus accumbens, is known to play an important role (Einhorn, LC, et al., Electrophysiological effect of cocaine in the mesoaccumbens dopamine system). : studies in the ventral tegmental area, J Neurosci., 8 (1) , pp. 100-112, 1988).

In a recent study due to the administration of cocaine, known as indicators of neuronal activity in drug addiction and related cheukhaek and projected areas of the striatum, including dopaminergic neurons of the early gene cF os (Immediate early gene cF os ) protein, c of There are reports of increased fos expression. Repeated administration of SKF-38393, a dopamine D1 receptor agonist, increased the expression of c-Fos, an indicator of gait activity and neuronal activity. In addition, the administration of dopamine antagonist SCH 23390 resulted in decreased cocaine-induced gait activity (Parada A., et al., Neuropharmacology , 39 (9) , pp. 1645-1652, 2000; Anderson SM et al. ., Administration of the D1-like dopmine receptor antagonist SCH-23390 into the medial nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug-seeking behavior in rats.Psychopharmacology (Berl) .168 (1-2) , pp.132- 138, 2003). In addition, in the experiments observed using in vivo microdialysis, the concentration of dopamine due to cocaine administration in the striatum and the nucleus, which are related to drug intoxication, increased significantly. This increase suggests experimental evidence that correlates the biochemical side dopamine with behavioral side gait activity.

Therefore, the identification of neural mechanisms involved in drug addiction may be the ultimate solution to drug addiction treatment.

Gentiana scabra var.buergeri max is the gentiana scabra Bunge var. Buergeri Maxim and dried roots and rhizomes of the same plant (Park Jong-hee, Lee Jung-kyu. (Commercial) Illustrated by Medicinal Plants pp.306-308, 2000), Geniopiacrin, a trisaccharide, and gentianose, a trisaccharide. Good health, antipyretic, anti-inflammatory, bile (, 미치는 韓 鍼灸, 韓 鍼灸, 韓 鍼灸, 미치는, 大 韓 鍼灸 學會 誌, 8 , pp.141-156, 1991) It has been reported to be effective in repairing liver damage along with its efficacy in the emergence (Han Sang-won, Yongdamcho and Shiho-su-acupuncture between CCl4-induced damage of rats and Korean acupuncture Journal, 10 (1) , pp. 297-313, 1993). Neither of the above documents discloses that chondroitin extracts are effective in drug addiction and withdrawal symptoms.

Therefore, the present inventors rapidly reduced c-Fos expression, which is an indicator of neuronal activity in the nucleus and striatum of the brain, as well as the effect of reducing gait activity, which is a behavioral sensitization reaction used as an index of drug addiction. By confirming the reduction, the present invention was completed by confirming the therapeutic effect of drug addiction and withdrawal symptoms.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of drug addiction and withdrawal symptom containing the chodone extract as an active ingredient.

In another aspect, the present invention provides a health functional food for the prevention and improvement of drug addiction and withdrawal symptoms containing choyong chok extract as an active ingredient.

Super eluted extracts as defined herein are water, lower alcohols of C ₁ to C ₄ or mixed solvents thereof, preferably water and ethanol mixed solvents, more preferably 60 to 100% ethanol mixed solvents, most preferably 90 To extracts soluble in 100% ethanol.

Drugs as defined herein are cocaine, (meth) amphetamine, nicotine, morphine, alcohol, cannabis or caffeine, and the like, preferably cocaine It is characterized by that.

Hereinafter, the present invention will be described in detail.

The super eluting extract of the present invention can be prepared as follows.

After drying by drying the super-dose, about 1 to 40 times the weight of the super-dose, preferably about 10 to 20 times the amount of water, C ₁ to C ₄ lower alcohol or a mixed solvent thereof, preferably water And an ethanol mixed solvent, more preferably 60 to 100% ethanol mixed solvent, extraction method such as hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction for about 10 to 96 hours, preferably 60 to 80 hours at room temperature. Preferably, the extract obtained after cold extraction is filtered, concentrated under reduced pressure or dried to obtain the super-solvent extract of the present invention.

The present invention provides a pharmaceutical composition for the prevention and treatment of drug addiction and withdrawal symptom, which contains the super-drug extract obtained by the above method as an active ingredient.

The composition of the present invention comprises 0.01 to 50% by weight of the extract relative to the total weight of the composition.

However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.

The composition comprising the super-solvent extract of the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.

Compositions comprising extracts according to the invention are formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Carriers, excipients and diluents which may be used in combination with the extract, and which may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.01 mg / kg to 10 g / kg, preferably 1 mg / kg to 1 g / kg per day. The administration may be carried out once a day or divided into several doses. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or Intracerebroventricular injection.

In another aspect, the present invention provides a health functional food for the prevention and improvement of drug addiction and withdrawal symptoms containing choyong chok extract as an active ingredient.

As defined herein, "health functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body under the Health Functional Food Act No. 6767, and "functional" means It means ingestion for the purpose of obtaining useful effects on health use such as nutrient control or physiological action on structure and function.

The composition comprising the extract of the present invention can be used in various ways, such as drugs, foods and drinks for the prevention and improvement of drug addiction and withdrawal symptoms. Examples of the food to which the chodose extract of the present invention may be added include various foods, beverages, gums, teas, vitamin complexes, health supplements, and the like, and are powders, granules, tablets, capsules, syrups or beverages. Available in form.

Chodoteul extract of the present invention is a drug that can be used safely even when taken for a long time for prevention purposes because there is little toxicity and side effects.

The extract of the present invention may be added to food or beverage for the purpose of preventing and treating drug addiction and withdrawal symptoms. At this time, the amount of the extract in the food or beverage is generally added to the health food composition of the present invention to 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.02 to 10 g based on 100 ml, preferably Can be added in a ratio of 0.3 to 1 g.

In addition to containing the extract as an essential ingredient in the indicated ratio, the health beverage composition of the present invention is not particularly limited in the liquid component and may contain various flavors or natural carbohydrates as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

Chodote extract of the present invention rapidly reduces the expression of c-Fos, which is an indicator of neuronal activity in the lateral nucleus and striatum of the brain, as well as a decrease in the amount of gait activity, a behavioral sensitization reaction used as an indicator of drug addiction. It can be usefully used as a pharmaceutical composition or health functional food for the prevention and treatment of drug addiction and withdrawal symptoms.

Hereinafter, the present invention will be described in detail by the following reference examples, examples and experimental examples.

However, the following reference examples, examples and experimental examples are merely to illustrate the invention, the content of the present invention is not limited by the following reference examples, examples and experimental examples.

Reference Example 1. Preparation of Laboratory Animals

The experimental animals used Sprague-Dawley male rats (Hyochang Science) weighing 250-260 g and were subjected to constant conditions (temperature: 21 ± 2 ℃, contrast: 12) in Daegu Haany University animal breeding room. In the time-contrast cycle, free intake of food and drinking water is allowed, and sufficient water and food are provided before the start of the experiment, and the test animals are pre-treated (handling) for 2 minutes a day for 3 days before the start of the experiment.

Reference Example 2. Statistical processing

Pedestrian activity was measured by horizontal movement distance (cm) in the box, and statistical significance was tested by the SPSS program (Version 11.01) post hoc Turkey test. Admitted.

Example 1. Preparation of Choga Extract

Purchasing from Daewon Pharmaceutical Co., Ltd. located in Daegu Metropolitan City, 4 liters of 95% ethanol was added to 200 g of dry and finely prepared choga, and the extract was extracted for 72 hours at room temperature (24 ℃). , Japan) to give 380 g of super eluted extract, which was used as a sample of the following experimental example (hereinafter referred to as "GXBM").

Experimental Example 1.Effect of Cho-Dong extract on behavioral sensitivity after drug administration

In order to confirm the effect of the superfluid extract (GXBM) of Example 1 on behavioral sensitivity due to acute and chronic drug administration, the method described in the literature on the change in gait activity of rats after cocaine administration was as follows. Application was carried out in the following manner (Karasinska JM., Et al., Eur Neurosci ., 22 (7) , pp.1741-1750, 2005).

1-1. How to measure amount of walking activity

The amount of activity of the experimental animals was measured by video tracking (Ethovision program, Noldus Information Technology BV, Wageningen, Netherlands) using videotracking. In detail, the horizontal movement of the test animal was traced using a black matt acrylic box of 40 cm × 40 cm × 45 cm in height, width, height, and height. By using a contrasting principle of a white subject on a black background, it transfers it to a computer and recognizes the center point of a white experimental animal image several times per second. The distance was quantified.

1-2. Measurement of ambulatory activity

The experimental animals prepared in Reference Example 1 were transferred to a laboratory where external noise was blocked in a kennel and weighed, respectively, and then placed in nine activity measuring boxes individually. After 90 minutes of adaptation in a box, 25 mg, 50 mg, and 100 mg / kg GXBM extracts were administered orally, respectively, and 1 ml / kg of vehicle [PEG + Tween 80+ EtOH + saline (control) 7: 1: 1: 1). Oral administration of a vehicle or super-dose extract, 60 minutes after a single dose of 20 mg / kg physiological saline or cocaine, and walking for an additional 60 minutes to measure the amount of walking activity in the horizontal moving distance (cm) in the box.

As shown in Table 1 and FIG. 1, the normal group (physiological saline treated group after vehicle administration) increased to 5183.59 ± 746.18 cm, and increased to 24958.15 ± 3594.84 cm in the control group (cocaine treated group after vehicle administration). , GXBM 25, 50, 100 mg / kg administration group, 28364.68 ± 3551.95 cm (p <0.951), 14862.08 ± 2765.79 cm (p <0.109), 12804.90 ± 2318.88 cm (p <0.035), respectively The amount of gait activity was decreased compared to the control group, and especially, the group treated with 100 mg / kg of superolead extract (GXBM) was significantly reduced compared to the control group.

In addition, in order to determine whether behavioral changes occur after administration of GXBM in normal condition, 100 mg / kg of the super-dose extract (super-dose alone group) was administered orally, followed by treatment with saline solution. As a result of measuring the amount of walking activity for 60 minutes, as shown in Figure 2 and Table 1, 5127.16 ± 1081.88 cm showed a similar pattern to the normal group did not show a significant effect in the normal state.

Experimental group Processing contents After cocaine administration
1 hour gait activity (cm) Normal Saline treated group after vehicle administration 5183.59 ± 746.18 Control group cocaine treatment after vehicle administration 24958.15 ± 3594.84 Super Gentian 25 mg / kg Cocaine treatment after 25 mg / kg 28364.68 ± 3551.95 Super Gentian 50 mg / kg Cocaine treatment after 50 mg / kg 14862.08 ± 2765.79 Super Gentian 100 mg / kg Cocaine treatment after the super-dose 100 mg / kg 12804.90 ± 2318.88 Cho Yongdam alone group Physiological saline treatment after administration of super-dose 100 mg / kg 5127.16 ± 1081.88

Experimental Example 2. Effect of Chondroitin extract on c-Fos Expression by Immunohistochemical Assay by Drug Administration

In order to confirm the expression of the initial gene c-Fos by drug administration of the super eluted extract (GXBM) obtained in Example 1, the following experiment was applied by applying the method described in the existing literature (NATHALIE THIRIET et al., Ann NY Acad.Sci., 914 , pp. 46-57, 2000)

On the day of the test, 100 mg / kg of superfluid extract (GXBM) was orally administered to the experimental animals, and 1 hour later, 20 mg / kg of cocaine was intraperitoneally administered and 2 hours thereafter, sodium phentobarbital (100 mg / kg). kg), followed by perfusion of blood through 500 ml of 4% paraformaldehyde (PFA) through the heart to fix brain tissue. After removing the brain tissue, it was fixed in 10% sucrose / 4% PFA for about 2 hours, soaked in 20% sucrose / phosphate buffer solution (PBS) solution and refrigerated at 4 ° C for one day. Maintained. Section brain tissue at 30 um thickness with cryotome (Shandon Cryotome, Thermo Fisher Scientific) at -20 ° C, take the nucleus and striatum, and place it in 0.1% sodium azide / PBS. Stored at ° C.

Tissue sections were washed three times in buffer (PBS) to remove lipids from the cell membrane in 2% Triton-X-100 / PBS solution for 5 minutes, and then blocked with 3% BSA / PBS solution. After reacting with a primary rabbit anti-Fos antibody (Santa cruz, CA, USA) diluted 1: 1000 in 0.1% BSA / PBS solution for 20 hours at 4 ° C., c- Fos protein was expressed.

As shown in FIG. 3 and FIG. 4, compared to the control group, 100 mg / kg of super eluted extract (GXBM) significantly reduced the expression of c-Fos gene, which is a neuronal activity indicator, in the nucleus and striatum. It was confirmed that there is.

Experimental Example 3. Acute Toxicity Test

In order to confirm the toxicity by administering the supernatant extract (GXBM) obtained in Example 1, the following experiment was applied by applying the method described in the existing literature (Hyung-Chul Lee et al., Journal of the Korean Society of Pathology , 15 (4) , pp. 543-47, 2001).

Acute toxicity test was performed using 6-week-old specific pathogen-free (SPF) SD rats. Two animals of each group were orally administered with a supernatant extract (GXBM) of the present invention at a dose of 500 mg / kg. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, and hematological and hematological examinations were performed.

As a result, no significant clinical symptoms or dead animals were noted in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings.

In addition, the super eluted extract of the present invention (GXBM) did not show a toxicity change in rats up to 500 mg / kg, respectively, and the minimum lethal dose (LD ₅₀ ) was determined to be a safe substance of 500 mg / kg or more.

Hereinafter, the preparation examples of the composition comprising the super-drug extract of the present invention (GXBM), but the present invention is not intended to limit it, but to explain in detail only.

Formulation Example 1 Preparation of Powder

Choongdam extract (GXBM) 20 mg

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2 Preparation of Tablet

Chondroitin extract (GXBM) 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components and tableting according to the conventional tablet manufacturing method to prepare a tablet.

Formulation Example 3 Preparation of Capsule

Chondroitin extract (GXBM) 10 mg

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium Stearate 0.2 mg

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation Example 4 Preparation of Injection

Chondroitin extract (GXBM) 10 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ , 12H ₂ O 26 mg

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

Formulation Example 5 Preparation of Liquid

Choongdam extract (GXBM) 20 mg

10 g of isomerized sugar

5 g of mannitol

Purified water

After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding lemon flavor appropriately, mixing the above components, adding purified water, adjusting the whole to 100 ml by adding purified water, and then filling into a brown bottle. The solution is prepared by sterilization.

Formulation Example 6 Preparation of Healthy Food

Choongdam extract (GXBM) 1000 mg

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

0.2 μg of vitamin B12

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

50 μg folic acid

Calcium Pantothenate 0.5mg

Mineral mixture quantity

Ferrous Sulfate 1.75 mg

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

15 mg of potassium phosphate monobasic

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

100 mg of calcium carbonate

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Formulation Example 7 Preparation of Healthy Drink

Choongdam extract (GXBM) 1000 mg

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to a total of 900 ml

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, &Lt; / RTI &gt;

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

[National R & D project supporting this invention]

[Task unique number]

B0009008

[Name of Buddha]

Ministry of Knowledge Economy

[Name of research project]

Herbal Biotechnology Research Center

[Name of Research Project]

Development of Herbal Medicine and Natural Products for the Treatment of Brain Disease

[Host]

Daegu Haany University Industry-Academic Cooperation Foundation

[Research Institute]

March 2009-February 2010

1 is a diagram showing the effect on the amount of gait activity of the supernatant extract (GXBM) induced by cocaine administration,

Figure 2 is a diagram showing the effect on the amount of gait activity when administered alone GXBM (100 mg / kg),

Figure 3 is a diagram showing the effect on the expression of c-Fos in the nucleus of the brain of supercoated extract (GXBM) induced by cocaine administration,

Figure 4 is a diagram showing the effect of c-Fos expression in the striatum of the supernatant extract of cocaine (GXBM) induced by cocaine administration.

Claims (6)

A pharmaceutical composition for the prevention and treatment of drug addiction and withdrawal symptoms, which contains Choyongcho extract as an active ingredient. The pharmaceutical composition according to claim 1, wherein the extract is an extract available in water, C ₁ to C ₄ lower alcohols, or a mixed solvent thereof. delete The pharmaceutical composition according to claim 1, comprising 0.01-50% by weight of the superdissolved extract based on the total weight of the composition. Health functional food for the prevention and improvement of drug addiction and withdrawal symptom containing Chodopcho extract as an active ingredient. 6. The dietary supplement of claim 5 which is a powder, granule, tablet, capsule, syrup or beverage.

Images